GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » EV-to-FCF

Raphael Pharmaceutical (Raphael Pharmaceutical) EV-to-FCF : -31.03 (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Raphael Pharmaceutical's Enterprise Value is $30.32 Mil. Raphael Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.98 Mil. Therefore, Raphael Pharmaceutical's EV-to-FCF for today is -31.03.

The historical rank and industry rank for Raphael Pharmaceutical's EV-to-FCF or its related term are showing as below:

RAPH' s EV-to-FCF Range Over the Past 10 Years
Min: -31.03   Med: 0   Max: 0
Current: -31.03

RAPH's EV-to-FCF is ranked worse than
100% of 532 companies
in the Drug Manufacturers industry
Industry Median: 22.76 vs RAPH: -31.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Raphael Pharmaceutical's stock price is $1.64. Raphael Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.180. Therefore, Raphael Pharmaceutical's PE Ratio for today is At Loss.


Raphael Pharmaceutical EV-to-FCF Historical Data

The historical data trend for Raphael Pharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical EV-to-FCF Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - -15.19

Raphael Pharmaceutical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.13 -22.65 -13.13 -15.19 -18.81

Competitive Comparison of Raphael Pharmaceutical's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphael Pharmaceutical's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's EV-to-FCF falls into.



Raphael Pharmaceutical EV-to-FCF Calculation

Raphael Pharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=30.318/-0.977
=-31.03

Raphael Pharmaceutical's current Enterprise Value is $30.32 Mil.
Raphael Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raphael Pharmaceutical  (OTCPK:RAPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Raphael Pharmaceutical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.64/-0.180
=At Loss

Raphael Pharmaceutical's share price for today is $1.64.
Raphael Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Raphael Pharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.
Executives
Joseph Press director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo director, 10 percent owner, officer: Chief Executive Officer 4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria director, officer: Chief Technology Officer 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay director C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash director
Guy Ofir director, 10 percent owner, officer: President 40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen director, 10 percent owner, officer: Secretary Treasurer Director 51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines